Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.62 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702696 | 0.81 | NCF1 (0.51) | GRM5ASIC3PDE10ANCF1KDR | |
| SCHEMBL31620747 | 0.79 | NPC1 (0.65) | NCF1NPC1RAB9ACASP3SENP7 | |
| SCHEMBL22134928 | 0.78 | NPC1 (0.49) | PDE10ANCF1NPC1RAB9AKDM4E | |
| SCHEMBL17995328 | 0.78 | NPC1 (0.52) | GRM5PDE10ANCF1NPC1RAB9A | |
| SCHEMBL5582792 | 0.77 | GRM5 (1.00) | GRM5ASIC3 | |
| SCHEMBL31109926 | 0.77 | NCF1 (0.50) | GRM5PDE10ANCF1NPC1RAB9A | |
| SCHEMBL21195763 | 0.77 | NCF1 (0.50) | GRM5PDE10ANCF1NPC1RAB9A | |
| SCHEMBL1702408 | 0.76 | IGF1R (0.57) | GRM5ASIC3KDRNPC1RAB9A | |
| SCHEMBL30363108 | 0.75 | GRM5 (0.63) | GRM5ASIC3KDRALDH1A1EGFR | |
| SCHEMBL21195524 | 0.75 | EGFR (0.55) | GRM5ASIC3NCF1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | claimed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | claimed |
| EP-2440545-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-04-24 | — | — | EP | claimed |
| US-9908869-B2 | Compounds useful for treating aids | ABIVAX (FR) | 2018-03-06 | — | — | US | claimed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | claimed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | claimed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | claimed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | claimed |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2014-09-25 | — | — | US | claimed |
| CN-102574835-B | Compounds for the treatment of cancer | SPLICOS SOC | 2014-04-16 | — | — | CN | claimed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | claimed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | claimed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | claimed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | claimed |
| CN-102625804-A | Compounds for the treatment of AIDS | SPLICOS SOC | 2012-08-01 | — | — | CN | claimed |
| CN-102596935-A | Compounds for the treatment of premature aging and especially premature aging | SPLICOS SOC | 2012-07-18 | — | — | CN | claimed |
| CN-102574835-A | Compounds for the treatment of cancer | SPLICOS SOC | 2012-07-11 | — | — | CN | claimed |
| EP-2440546-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR1, CNR1, CBR3 | GRM5 217/4885ASIC3 3162/4885PDE10A 3772/4885 |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | NR1H3, NR3C1, NR3C2 | GRM5 131/4885ASIC3 1692/4885PDE10A 3381/4885 |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CBR1, CBR3, NCOR1 | GRM5 155/4885ASIC3 2816/4885PDE10A 4570/4885 |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | NR2C2, NCOR2, NR4A2 | GRM5 362/4885ASIC3 3283/4885PDE10A 2845/4885 |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | RCOR1, CBR1, RCOR3 | GRM5 261/4885ASIC3 3425/4885PDE10A 4667/4885 |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | GRM5 263/4885ASIC3 952/4885PDE10A 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.